• Users Online:567
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 
LETTER TO EDITOR
Ahead of print publication  

Feasibility and safety of EUS-guided radiofrequency ablation in treatment of locally advanced, unresectable pancreatic cancer


1 Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, Zhejiang Province, China
2 Department of Gastroenterology, Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
3 Department of Gastroenterology, Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, Zhejiang Province, China

Date of Submission09-Jan-2021
Date of Acceptance01-Mar-2021
Date of Web Publication12-May-2021

Correspondence Address:
Jianfeng Yang,
Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, Nanjing Medical University, #261 Huansha Road, Hangzhou, 310006, Zhejiang province
China
Xiaofeng Zhang,
Department of Gastroenterology, Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Nanjing Medical University, #261 Huansha Road, Hangzhou, 310006, Zhejiang province
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/EUS-D-21-00013

PMID: 34003141



How to cite this URL:
Jiang J, Lou Q, Yang J, Zhang X. Feasibility and safety of EUS-guided radiofrequency ablation in treatment of locally advanced, unresectable pancreatic cancer. Endosc Ultrasound [Epub ahead of print] [cited 2021 Jun 21]. Available from: http://www.eusjournal.com/preprintarticle.asp?id=315907

Dear Editor,

Local radiofrequency ablation (RFA) technology is being developed as supplementary therapy in multimodal therapy strategy of unresectable nonmetastatic tumor.[1] However, the clinical application of intraoperative or percutaneous RFA for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events.[2] Hence, we did a study to evaluate the feasibility and safety of EUS-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.

Eight patients with unresectable PDAC (mean age: 74.3 ± 6.3 years; 5 [62.5%] males) who underwent EUS-RFA were included. Five tumors located in the pancreatic head, two in the pancreatic body, while one in the pancreatic tail. The Habib™ EUS RFA probe (EMcision Ltd., London, UK) was properly placed into the target lesion, and the RFA was performed within 90–120 s at 5 W under real-time EUS surveillance. The mean time of a single RFA session was 226.3 s (120–360 s), with a mean number of applications of 2.4 (range 1–4). Seven patients with severe neoplastic pain underwent EUS-guided celiac plexus neurolysis (EUS-CPN) during the same session before the RFA procedure. The mean tumor sizes measured by EUS 1-month postprocedure were significantly reduced than that at preprocedure (46.9 mm × 38.1 mm vs. 39.5 mm × 29.5 mm); the pancreatic cancer mass was reduced by 34.3% 1 month after RFA treatment. The mean survival of the patients after EUS-RFA was 10.7 months and 16.1 months from the diagnosis [Table 1]. All patients did not have serious early adverse events. Only mild abdominal pain and mild pancreatitis occurred, suggesting that the power of 5 W and the time of 90–120 s were safe. Six patients received CPN before RFA and the abdominal pain was significantly relieved. This suggests that EUS-CPN could perform with EUS-RFA together.
Table 1: EUS-radiofrequency ablation procedure details, change of tumor size and level of CA19-9, progression-free survival, and overall survival of the patients

Click here to view


The limitation of this study is that there is no control group and it is a single-center study with a small sample size. Randomized, large-sample, multicenter studies are needed to shed light on the efficacy of EUS-RFA, to optimize RFA parameter (such as ablation time, power, and interval time), and to explore whether the survival time of patients can be further improved by RFA and combined chemotherapy.

In conclusion, EUS-RFA is a feasible and safe treatment for unresectable locally advanced pancreatic cancer, especially for patients with multiple comorbidities who were intolerance to chemotherapy due to side effects.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

The study was supported by grants from Hangzhou Municipal Health Commission (2017ZD01), Zhejiang Provincial Health Commission (2018PY037, 2019ZD017), and Hangzhou Science and Technology Commission (20162013A01), China.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Geboers B, Ruarus AH, Nieuwenhuizen S, et al. Needle-guided ablation of locally advanced pancreatic cancer: Cytoreduction or immunomodulation by in vivo vaccination? Chin Clin Oncol 2019;8:61.  Back to cited text no. 1
    
2.
Ierardi AM, Lucchina N, Bacuzzi A, et al. Percutaneous ablation therapies of inoperable pancreatic cancer: A systematic review. Ann Gastroenterol 2015;28:431-9.  Back to cited text no. 2
    



 
 
    Tables

  [Table 1]



 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Jiang J
    -  Lou Q
    -  Yang J
    -  Zhang X
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Tables

 Article Access Statistics
    Viewed314    
    PDF Downloaded8    

Recommend this journal